These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 21322021)

  • 61. Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
    Isaacson SH; Boroojerdi B; Waln O; McGraw M; Kreitzman DL; Klos K; Revilla FJ; Heldman D; Phillips M; Terricabras D; Markowitz M; Woltering F; Carson S; Truong D
    Parkinsonism Relat Disord; 2019 Jul; 64():132-137. PubMed ID: 30948242
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.
    Wang Y; Yang Y; Wu H; Lan D; Chen Y; Zhao Z
    J Clin Sleep Med; 2016 Oct; 12(10):1403-1409. PubMed ID: 27568909
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
    Chen F; Jin L; Nie Z
    J Pharm Pharm Sci; 2017; 20(0):285-294. PubMed ID: 28810946
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study.
    Suzuki K; Funakoshi K; Fujita H; Hirata K
    Clin Neuropharmacol; 2022 May-Jun 01; 45(3):61-64. PubMed ID: 35579485
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
    Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
    Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
    [TBL] [Abstract][Full Text] [Related]  

  • 66. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 69. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
    Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
    Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
    Rascol O; Perez-Lloret S
    Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine.
    Malik M; Andreas JO; Hnatkova K; Hoeckendorff J; Cawello W; Middle M; Horstmann R; Braun M
    Clin Pharmacol Ther; 2008 Nov; 84(5):595-603. PubMed ID: 18650802
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.
    Koch G; Motta C; Bonnì S; Pellicciari MC; Picazio S; Casula EP; Maiella M; Di Lorenzo F; Ponzo V; Ferrari C; Scaricamazza E; Caltagirone C; Martorana A
    JAMA Netw Open; 2020 Jul; 3(7):e2010372. PubMed ID: 32667654
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease.
    Vallderiola F; Compta Y; Aparicio J; Tarradellas J; Salazar G; Oliver JM; Callén A; Delgado T; Nobbe F
    Parkinsons Dis; 2015; 2015():475630. PubMed ID: 26576319
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
    Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
    Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
    LeWitt PA; Lyons KE; Pahwa R;
    Neurology; 2007 Apr; 68(16):1262-7. PubMed ID: 17438216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.